aap: Q2/2015 sales above guidance at EUR 6.5 million; 27% LOQTEQ® growth in H1/2015
(Thomson Reuters ONE) -
aap Implantate AG /
aap: Q2/2015 sales above guidance at EUR 6.5 million; 27% LOQTEQ® growth in
H1/2015
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) generated sales totalling EUR 6.5 million in
the second quarter of 2015 (Q2/2014: EUR 8.1 million) according to preliminary
figures, thereby exceeding the guidance provided in May of EUR 5.0 million to
EUR 6.1 million. Total sales in the first half of the current financial year
thus amounted to EUR 13.6 million (H1/2014: EUR 14.2 million).
+----------------------+---------+---------+--------+
| | | | |
| Sales in EUR million | Q2/2015 | Q2/2014 | Change |
+----------------------+---------+---------+--------+
| Trauma | 3.2 | 2.9 | 8% |
| | | | |
| thereof LOQTEQ® | 2.0 | 1.8 | 15% |
+----------------------+---------+---------+--------+
| Biomaterials | 3.2 | 4.9 | -34% |
+----------------------+---------+---------+--------+
| Projects | 0.0 | 0.1 | -82% |
+----------------------+---------+---------+--------+
| Other | 0.1 | 0.2 | -50% |
+----------------------+---------+---------+--------+
| Total sales | 6.5 | 8.1 | -20% |
+----------------------+---------+---------+--------+
+----------------------+---------+---------+--------+
| | | | |
| Sales in EUR million | H1/2015 | H1/2014 | Change |
+----------------------+---------+---------+--------+
| Trauma | 5.6 | 5.1 | 11% |
| | | | |
| thereof LOQTEQ® | 3.7 | 2.9 | 27% |
+----------------------+---------+---------+--------+
| Biomaterials | 7.6 | 8.4 | -9% |
+----------------------+---------+---------+--------+
| Projects | 0.2 | 0.2 | 10% |
+----------------------+---------+---------+--------+
| Other | 0.2 | 0.5 | -72% |
+----------------------+---------+---------+--------+
| Total sales | 13.6 | 14.2 | -4% |
+----------------------+---------+---------+--------+
In the second quarter of 2015, aap Implantate AG increased its LOQTEQ® portfolio
sales by 15% compared to the corresponding period in the last year to EUR 2.0
million (Q2/2014: EUR 1.8 million). Sustained by the positive sales development
of the LOQTEQ® product family, overall sales in the trauma business were up by
8% year-on-year to EUR 3.2 million (Q2/2014: EUR 2.9 million).
In the biomaterials business the company generated sales of EUR 3.2 million
(Q2/2014: EUR 4.9 million) in the second quarter of the current financial year.
This decline was merely a quarterly fluctuation primarily due to the ordering
behaviour of the major customers in the area of bone cement and mixing systems.
In the first half of 2015 aap Implantate AG continued the positive sales
development of the LOQTEQ® portfolio with an increase of 27% year-on-year to EUR
3.7 million (H1/2014: EUR 2.9 million). In the biomaterials business the company
realized sales of EUR 7.6 million (H1/2014: EUR 8.4 million) in the first six
months of the current financial year.
The preliminary results contained in this press release are based on
management's initial analysis of operations for the period ended on 30 June
2015, and are therefore subject to change. aap Implantate AG plans to announce
its final results for the second quarter respectively the first half of 2015 on
14 August 2015.
About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered
in Berlin, Germany. The company develops, manufactures and markets trauma and
biomaterials products for orthopedics. The trauma portfolio includes besides the
innovative anatomical plating system LOQTEQ® a wide range of cannulated screws
as well as standard plates and screws. In the biomaterials business the company
is specialized on bone cements and mixing systems. In German-speaking countries
aap Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of distributors in
more than 60 countries at the international level. In the biomaterials business
sales are handled via OEM and private label cooperations with several selected
international orthopedic and trauma companies. aap Implantate AG's stock is
listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA:
AAQ.DE). For more information, please visit www.aap.de, or download the
Company's investor relations app from the Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
For inquiries please contact: aap Implantate AG, Fabian Franke, Investor
Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke(at)aap.de
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via GlobeNewswire
[HUG#1939102]
Unternehmensinformation / Kurzprofil:
Datum: 16.07.2015 - 15:40 Uhr
Sprache: Deutsch
News-ID 407339
Anzahl Zeichen: 7196
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 128 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap: Q2/2015 sales above guidance at EUR 6.5 million; 27% LOQTEQ® growth in H1/2015"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
